Co-administration of bradykinin analogs in animal models yielded increased carboplatin concentrations in brain tumor tissue without serious toxicities.13,14 However, bradykinin analogs combined with carboplatin in patients with recurrent brain tumors did not result in therapeutic benefits in these patients.15 The gene discussed is KNG1; the disease is brain neoplasm.